BioSpace News Archive

Myrtelle Inc. announced that Christopher Janson, M.D., Principal Investigator on Myrtelle’s Canavan Disease Gene Therapy Trial and Associate Professor of Neuroscience & Founding Director of Human Gene Therapy Center at Premier Health Wright State Neuroscience Institute in Dayton, Ohio.

Sensus Healthcare, Inc. announces the shipment of an SRT-100+™ System to Cape Cod Hospital in Hyannis, Massachusetts, the second SRT-100+ System sold to a hospital in Massachusetts.

NANO-X IMAGING LTD announced that HealthCCSng, an AI-powered solution created by Nanox’s deep-learning medical imaging analytics subsidiary, Nanox.AI, was used in a clinical study evaluating routine CT scans and found that 58% of patients unknowingly had moderate to severe levels of coronary artery calcium, a proven indicator of future cardiac events.

Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced FDA and Health Canada clearance of the expansion portion of the ongoing COVALENT-111 Phase II study.

AnHeart Therapeutics (“AnHeart”), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, today announced the appointment of Charlotte Arnold as Chief Corporate Affairs Officer.

PurMinds NeuroPharma (“PurMinds” or the “Company”), a neuroscience company with a robust clinical pipeline combining small molecules, psychedelic compounds and other modalities

ProofPilot announced today a strategic collaboration with global pharmaceutical leader Eli Lilly and Company (Lilly) to offer Lilly’s patent-pending, sensor cloud platform, Magnol.AI™, a state-of-the-art platform that enables sophisticated management of high-frequency sensor data with security and ease, as part of ProofPilot’s technology solution.

In some patients, infection with the pandemic virus SARS-CoV-2 can trigger a dangerous immune response in hardened fatty deposits lining the heart’s largest blood vessels, a new study shows.

PIC Therapeutics announced that Richard Gedrich, PhD has joined its Leadership Team as Chief Development Officer.

Health Canada has authorized the use of the Pfizer-BioNTech Comirnaty COVID-19 vaccine targeting the Omicron XBB.1.5 subvariant for individuals six months of age and older.